tiprankstipranks
Trending News
More News >
Jagsonpal Pharmaceuticals Ltd. (IN:JAGSNPHARM)
:JAGSNPHARM
India Market
Advertisement

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) AI Stock Analysis

Compare
2 Followers

Top Page

IN:JAGSNPHARM

Jagsonpal Pharmaceuticals Ltd.

(JAGSNPHARM)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
₹262.00
▲(20.10% Upside)
Jagsonpal Pharmaceuticals Ltd. has a strong financial foundation with solid growth and profitability, which is the most significant factor in its overall score. However, technical indicators suggest bearish momentum, and the valuation is moderate, which tempers the overall attractiveness of the stock.

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) vs. iShares MSCI India ETF (INDA)

Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model

Company DescriptionJagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.
How the Company Makes MoneyJagsonpal Pharmaceuticals Ltd. primarily generates revenue through the sale of its pharmaceutical products. The company manufactures and markets a variety of branded and generic formulations, catering to different therapeutic areas. Its revenue streams include domestic sales within India, which form a significant portion of its income, as well as international sales through exports. Key revenue drivers include its focus on specialty segments such as gynecology and orthopedics, which are high-demand areas in the pharmaceutical market. Additionally, partnerships with healthcare professionals, distributors, and strategic alliances play a critical role in expanding its market reach and enhancing its revenue-generating capabilities.

Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview

Summary
Jagsonpal Pharmaceuticals Ltd. exhibits strong financial performance with robust revenue growth, healthy profit margins, and a solid balance sheet characterized by low leverage. Cash flow generation is positive, supporting reinvestment and dividends, though there is some variability in free cash flow growth.
Income Statement
85
Very Positive
Jagsonpal Pharmaceuticals Ltd. has demonstrated strong revenue growth over the years, with a notable increase in net income as well. Gross profit margin and net profit margin are healthy, indicating efficient cost management and profitability. The increase in EBIT and EBITDA margins further underscores the company's operational efficiency. Overall, the income statement reflects a robust and growing financial performance.
Balance Sheet
82
Very Positive
The company's balance sheet is solid, characterized by a strong equity base and a low debt-to-equity ratio, indicating low leverage and financial stability. The equity ratio is high, showcasing a strong asset base funded by equity rather than debt. This structure mitigates financial risk and provides a foundation for sustainable growth. However, the decline in cash and short-term investments over time could be a point of concern for liquidity management.
Cash Flow
78
Positive
Cash flow analysis shows a positive trajectory in operating cash flow and free cash flow, which supports the company's capacity to reinvest and pay dividends. The operating cash flow to net income ratio is strong, highlighting effective conversion of earnings into cash. However, the free cash flow growth rate has shown some variability, which could indicate fluctuations in capital expenditures or cash management.
BreakdownTTMDec 2025Dec 2024Dec 2022Dec 2022Dec 2021
Income Statement
Total Revenue2.69B2.69B2.09B2.26B2.37B1.88B
Gross Profit1.32B1.72B652.59M1.30B1.44B1.07B
EBITDA761.18M510.71M323.46M284.53M363.96M234.72M
Net Income553.61M553.61M224.63M188.55M267.21M170.58M
Balance Sheet
Total Assets2.78B2.78B2.17B1.68B1.95B1.64B
Cash, Cash Equivalents and Short-Term Investments1.29B1.29B1.48B472.77M1.15B618.82M
Total Debt92.39M92.39M89.41M0.0060.01M67.88M
Total Liabilities383.10M383.10M296.76M375.99M360.56M422.73M
Stockholders Equity2.40B2.40B1.87B1.31B1.59B1.22B
Cash Flow
Free Cash Flow0.00549.52M349.18M51.31M463.37M277.53M
Operating Cash Flow0.00553.00M351.66M55.98M466.54M282.22M
Investing Cash Flow0.00-451.47M-245.48M-262.08M-576.71M-22.64M
Financing Cash Flow0.00-116.98M-89.11M-123.04M-4.57M-68.28M

Jagsonpal Pharmaceuticals Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price218.15
Price Trends
50DMA
248.20
Negative
100DMA
236.41
Negative
200DMA
233.15
Negative
Market Momentum
MACD
-4.78
Positive
RSI
34.57
Neutral
STOCH
13.61
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Negative. The current price of 218.15 is below the 20-day moving average (MA) of 238.83, below the 50-day MA of 248.20, and below the 200-day MA of 233.15, indicating a bearish trend. The MACD of -4.78 indicates Positive momentum. The RSI at 34.57 is Neutral, neither overbought nor oversold. The STOCH value of 13.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JAGSNPHARM.

Jagsonpal Pharmaceuticals Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
₹14.29B23.401.17%34.72%196.94%
68
Neutral
₹16.46B43.778.75%0.36%4.68%94.22%
65
Neutral
₹12.13B-133.777.41%0.38%-6.86%-118.14%
63
Neutral
₹15.32B14.338.03%0.34%4.93%29.92%
54
Neutral
₹14.92B32.908.47%0.21%17.50%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
218.15
52.18
31.44%
IN:BAJAJHCARE
Bajaj Healthcare Ltd
489.85
114.38
30.46%
IN:BLISSGVS
Bliss Gvs Pharma Limited
146.80
15.72
11.99%
IN:HESTERBIO
Hester Biosciences Limited
1,918.75
-517.15
-21.23%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
532.70
-134.95
-20.21%
IN:THEMISMED
Themis Medicare Limited
130.31
-140.82
-51.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 23, 2025